HYPEBEAST(00150.HK):首財季收益、毛利創新高
HYPEBEAST(00150.HK)公布,截至6月底止首財季,收益、毛利及毛利率方面均創下新高。
收益按年增加57.9%至2.01億元,主要歸因於集團媒體分部之已簽訂合約價值的增加、客戶類別的擴展及區域市場的增長。
已簽訂合約價值分別較上一年度及2020年財政年度第一季COVID-19疫情前水平大幅上升111.9%及74.7%,主要由於製作能力提高及品牌客戶類別增加。
毛利按年增131.1%至1.17億元,毛利率增18.5個百分點至58.3%,主因媒體分部的媒體製作規模擴大及更精簡地交付活動,加上電子商務及零售分部以正價銷售的產品比例上升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.